Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer

Published:2023-03 Issue: Volume:943 Page:175565
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Nalla Lakshmi Vineela,Khairnar Amit^ORCID

Publisher

Elsevier BV

Subject

Pharmacology

Reference47 articles.

1. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: emerging approach for new application;Abdelhamid;Biomed. Pharmacother.,2022

2. Prospective identification of tumorigenic breast cancer cells;Al-Hajj;Proc. Natl. Acad. Sci. U. S. A.,2003

3. Novel insights into the function of CD24: a driving force in cancer;Altevogt;Int. J. Cancer,2021

4. PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation;Azoitei;Mol. Cancer,2016

5. Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer;Bora;Life Sci.,2021

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On-demand Opto-Laser activatable nanoSilver ThermoGel for treatment of full-thickness diabetic wound in a mouse model;Biomaterials Advances;2024-11

2. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies;European Journal of Pharmacology;2024-09

3. Empagliflozin drives ferroptosis in anoikis-resistant cells by activating miR-128-3p dependent pathway and inhibiting CD98hc in breast cancer;Free Radical Biology and Medicine;2024-08

4. SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells;Cellular & Molecular Biology Letters;2024-05-29

5. Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies;Medical Oncology;2024-04-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3